Accrued Expenses and Restructuring Reserve (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019		Dec. 31, 2018
Accrued Expenses and Other Liabilities [Abstract]
Accrued research and development costs	$ 172,190		$ 71,329
Accrued professional fees	221,528		421,617
Accrued compensation	45,244		54,269
Accrued other	0		46,674
Accrued rent	8,000		8,000
Total	446,962		601,889
Restructuring Reserve [Abstract]
Restructuring reserve	1,948,596	[1]	0
Total	1,948,596		$ 0
Restructuring expense	$ 121,675

[1] Restructuring reserve relates to the severance costs incurred by Edge Therapeutics prior to the merger transaction and assumed by the Company as part of the purchase accounting, but not yet paid. Restructuring reserve relates to the severance costs incurred by Edge Therapeutics prior to the merger transaction and assumed by the Company as part of the purchase accounting, but not yet paid. For the three months ended March 31, 2019, the Company incurred $121,675 of restructuring expense which is recognized within general and administrative expense.